EC
NMRA icon

EcoR1 Capital’s Neumora Therapeutics NMRA Stock Holding History

EcoR1 Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,071,450
Closed -$22M – 59
2024
Q4 		$22M Hold
2,071,450
– – 0.83% 26
2024
Q3 		$27.4M Hold
2,071,450
– – 0.94% 25
2024
Q2 		$20.4M Hold
2,071,450
– – 0.62% 35
2024
Q1 		$28.5M Hold
2,071,450
– – 0.72% 26
2023
Q4 		$35.3M Hold
2,071,450
– – 0.92% 20
2023
Q3 		$29.2M Buy
+2,071,450
New +$25.9M 0.99% 20

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

EcoR1 Capital's NMRA Position: Q1 2025 in Review

EcoR1 Capital sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 2,071,450 shares — an estimated $22M sold.

EcoR1 Capital first reported a position in NMRA in Q3 2023 and held it in 6 quarters. The position peaked at $35.3M in Q4 2023. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • EcoR1 Capital reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EcoR1 Capital sold 2,071,450 Neumora Therapeutics shares in Q1 2025, an estimated $22M.
  • EcoR1 Capital first reported a position in Neumora Therapeutics in Q3 2023 and held it in 6 quarters.
  • EcoR1 Capital's Neumora Therapeutics position peaked at $35.3M in Q4 2023.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.